Oct 06, 2016 8:00 am EDT CymaBay Therapeutics Announces an Oral Presentation Describing the Efficacy of MBX-8025 in a Preclinical Model of NASH at the AASLD 2016 Liver Meeting
Oct 05, 2016 8:00 am EDT CymaBay Therapeutics Announces Plans to Initiate Its Next Phase 2 Study of MBX-8025 in Primary Biliary Cholangitis
Sep 08, 2016 8:00 am EDT CymaBay Therapeutics to Present at Rodman & Renshaw 18th Annual Global Investment Conference
Aug 02, 2016 8:00 am EDT CymaBay to Announce Second Quarter 2016 Financial Results on Tuesday, August 9
Jul 07, 2016 8:00 am EDT CymaBay Announces Participation at Cantor Fitzgerald Healthcare Conference on July 12th in New York
May 31, 2016 7:00 am EDT CymaBay Therapeutics Announces Top Line Efficacy and Safety Data From Its Phase 2 Study of Mbx-8025 in Patients With Primary Biliary Cholangitis (PBC)
May 02, 2016 8:00 am EDT CymaBay to Announce First Quarter 2016 Financial Results on Wednesday, May 11